

Middle East Biomarker-Based Immunoassays Market Size, Share & Trends Analysis Report By Sample (Blood, Saliva) By Product (Reagents & Kits, Consumables), By Biomarker, By Diseases, By End Use, By Region, And Segment Forecasts, 2025 - 2033

<https://marketpublishers.com/r/MFD8305020ABEN.html>

Date: September 2025

Pages: 150

Price: US\$ 5,950.00 (Single User License)

ID: MFD8305020ABEN

Abstracts

Middle East Biomarker-Based Immunoassays Market Summary

The Middle East biomarker-based immunoassays market size was estimated at USD 114.23 million in 2024 and is projected to reach USD 159.25 million by 2033, growing at a CAGR of 3.61% from 2025 to 2033. The market growth is driven by the rising global burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which require precise and early diagnostic tools. Increasing demand for personalized medicine has led clinicians and pharmaceutical companies to adopt biomarker-guided strategies, where immunoassays play a central role in both disease detection and therapeutic monitoring.

Countries such as Saudi Arabia, the UAE, and Kuwait are growing and investing heavily in diagnostic infrastructure and adopting international best practices. A growing trend in the market is the push for deeper partnerships between global diagnostic firms and local healthcare providers. A recent example came in January 2025, when Diatech Pharmacogenetics broadened its work with Merck to give colorectal cancer patients in the Middle East better access to RAS biomarker testing. Moves like this show how strongly the region is leaning toward personalized cancer care. These alliances do not just improve the reach of biomarker assays—they also bring new technologies into local systems and build expertise on the ground. For many international companies, the Middle East is starting to look like one of the most promising areas for growth in precision diagnostics.

The Middle East region offers untapped potential for biomarker-based immunoassays due to its expanding healthcare infrastructure and growing demand for precision medicine. Governments in countries like Saudi Arabia and the UAE have been putting serious money into diagnostic capacity so they do not have to rely as much on overseas labs. That shift is opening the door for local manufacturing and technology transfer. At the same time, lifestyle-driven diseases are becoming more common, which makes early detection and personalized treatment more important in areas such as oncology, cardiology, and neurology. With more attention now on value-based care, biomarker testing is seen as a practical way to lower costs while still improving patient outcomes.

Strategic collaborations are playing an important role in driving the Middle East biomarker ecosystem. In 2025, Diatech Pharmacogenetics expanded its partnership with Merck to improve colorectal cancer care in the region through RAS biomarker testing, highlighting the momentum in companion diagnostics. Similarly, partnerships between diagnostic technology providers like IBL International and Grifols are advancing biomarker panels that could see uptake in the Middle East's expanding clinical research networks. In the meantime, regional organizations are demonstrating their dedication to becoming a center for precision diagnostics innovation by introducing cutting-edge biomarker testing programs that work with international standards, such as King Faisal Specialist Hospital in Saudi Arabia.

Middle East Biomarker-Based Immunoassays Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Middle East biomarker-based immunoassays market report based on sample, product, biomarkers, diseases, end use, and region:

Sample Outlook (Revenue, USD Million, 2021 - 2033)

Blood

Tissue

Urine

Saliva

Product Outlook (Revenue, USD Million, 2021 - 2033)

Consumables

Instruments/Analyzers

Reagent & Kits

Services

Biomarker Outlook (Revenue, USD Million, 2021 - 2033)

Safety & toxicity biomarkers

Efficacy & Pharmacodynamic Biomarkers

Predictive & Prognostic Biomarkers

Surrogate/Exploratory Biomarkers

Diseases Outlook (Revenue, USD Million, 2021 - 2033)

Cancer

Cardiovascular Diseases

Neurological Diseases

Immunological Diseases

Others

End Use Outlook (Revenue, USD Million, 2021 - 2033)

Hospitals & Clinics

Diagnostic Laboratories

Research & Academic Institutes

Others

Regional Outlook (Revenue, USD Million, 2021 - 2033)

Middle East

Saudi Arabia

UAE

Kuwait

Oman

Qatar

Rest of Middle East

This report can be delivered to the clients within 2 Business Days

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
 - 1.2.1. Sample Segment
 - 1.2.2. Product Segment
 - 1.2.3. Biomarker Segment
 - 1.2.4. Diseases Segment
 - 1.2.5. End Use Segment
- 1.3. Information analysis
 - 1.3.1. Market formula, tion & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
 - 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Biomarker
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
 - 1.10.1. Objective
 - 1.10.2. Objective

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape

CHAPTER 3. MIDDLE EAST BIOMARKER-BASED IMMUNOASSAYS MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent market outlook
 - 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
 - 3.2.1. Market driver analysis
 - 3.2.1.1. Rising demand for precision medicine and personalized therapies

- 3.2.1.2. Increasing prevalence of chronic and infectious diseases
- 3.2.1.3. Technological advancements in immunoassay platforms
- 3.2.2. Market restraint analysis
 - 3.2.2.1. High cost of advanced biomarker assays and platforms
- 3.3. Middle East Biomarker-Based Immunoassays Market Analysis Tools
 - 3.3.1. Industry Analysis – Porter's
 - 3.3.2. PESTEL Analysis

CHAPTER 4. MIDDLE EAST BIOMARKER-BASED IMMUNOASSAYS MARKET: SAMPLE ESTIMATES & TREND ANALYSIS

- 4.1. Segment Dashboard
- 4.2. Middle East Biomarker-Based Immunoassays Market Sample Movement Analysis
- 4.3. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by sample, 2018 to 2033 (USD Million)
- 4.4. Blood
 - 4.4.1. Blood market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5. Tissue
 - 4.5.1. Tissue market estimates and forecasts 2021 to 2033 (USD Million)
- 4.6. Saliva
 - 4.6.1. Saliva market estimates and forecasts 2021 to 2033 (USD Million)
- 4.7. Urine
 - 4.7.1. Urine market estimates and forecasts 2021 to 2033 (USD Million)

CHAPTER 5. MIDDLE EAST BIOMARKER-BASED IMMUNOASSAYS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS

- 5.1. Segment Dashboard
- 5.2. Middle East Biomarker-Based Immunoassays Market Product Movement Analysis
- 5.3. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
- 5.4. Consumables
 - 5.4.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5. Instruments/Analyzers
 - 5.5.1. Instruments/Analyzers market estimates and forecasts 2021 to 2033 (USD Million)
- 5.6. Reagent & Kits
 - 5.6.1. Reagent & kits market estimates and forecasts 2021 to 2033 (USD Million)
- 5.7. Services

5.7.1. Services market estimates and forecasts 2021 to 2033 (USD Million)

CHAPTER 6. MIDDLE EAST BIOMARKER-BASED IMMUNOASSAYS MARKET: BIOMARKER ESTIMATES & TREND ANALYSIS

6.1. Segment Dashboard

6.2. Middle East Biomarker-Based Immunoassays Market Biomarker Movement Analysis

6.3. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by biomarkers, 2021 to 2033 (USD Million)

6.4. Safety & toxicity biomarkers

6.4.1. Safety & toxicity biomarkers market estimates and forecasts 2021 to 2033 (USD Million)

6.5. Efficacy & Pharmacodynamic Biomarkers

6.5.1. Efficacy & Pharmacodynamic Biomarkers market estimates and forecasts 2021 to 2033 (USD Million)

6.6. Predictive & Prognostic Biomarkers

6.6.1. Predictive & prognostic biomarkers market estimates and forecasts 2021 to 2033 (USD Million)

6.7. Surrogate/Exploratory Biomarkers

6.7.1. Surrogate/exploratory biomarkers market estimates and forecasts 2021 to 2033 (USD Million)

CHAPTER 7. MIDDLE EAST BIOMARKER-BASED IMMUNOASSAYS MARKET: DISEASES ESTIMATES & TREND ANALYSIS

7.1. Segment Dashboard

7.2. Middle East Biomarker-Based Immunoassays Market Diseases Movement Analysis

7.2.1. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by diseases, 2021 to 2033 (USD Million)

7.3. Cancer

7.3.1. Cancer market estimates and forecasts 2021 to 2033 (USD Million)

7.4. Cardiovascular Diseases

7.4.1. Cardiovascular diseases market estimates and forecasts 2021 to 2033 (USD Million)

7.5. Neurological Diseases

7.5.1. Neurological diseases market estimates and forecasts 2021 to 2033 (USD Million)

7.6. Immunological Diseases

7.6.1. Immunological diseases testing market estimates and forecasts 2021 to 2033 (USD Million)

7.7. Others

7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

CHAPTER 8. MIDDLE EAST BIOMARKER-BASED IMMUNOASSAYS MARKET: END USE ESTIMATES & TREND ANALYSIS

8.1. Segment Dashboard

8.2. Middle East Biomarker-Based Immunoassays Market End Use Movement Analysis

8.2.1. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)

8.3. Hospitals & Clinics

8.3.1. Hospitals and clinics market estimates and forecasts 2021 to 2033 (USD Million)

8.4. Diagnostic Laboratories

8.4.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)

8.5. Research & Academic Institutes

8.5.1. Research & Academic Institutes market estimates and forecasts 2021 to 2033 (USD Million)

8.6. Others

8.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

CHAPTER 9. MIDDLE EAST BIOMARKER-BASED IMMUNOASSAYS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

9.1. Regional Dashboard

9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:

9.3. Middle East

9.3.1. Oman

9.3.1.1. Key country dynamics

9.3.1.2. Regulatory framework/ reimbursement structure

9.3.1.3. Competitive scenario

9.3.1.4. Oman market estimates and forecasts 2021 to 2033 (USD Million)

9.3.2. Saudi Arabia

9.3.2.1. Key country dynamics

9.3.2.2. Regulatory framework/ reimbursement structure

9.3.2.3. Competitive scenario

9.3.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)

9.3.3. UAE

9.3.3.1. Key country dynamics

9.3.3.2. Regulatory framework/ reimbursement structure

9.3.3.3. Competitive scenario

9.3.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)

9.3.4. Kuwait

9.3.4.1. Key country dynamics

9.3.4.2. Regulatory framework/ reimbursement structure

9.3.4.3. Competitive scenario

9.3.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

9.3.5. Qatar

9.3.5.1. Key country dynamics

9.3.5.2. Regulatory framework/ reimbursement structure

9.3.5.3. Competitive scenario

9.3.5.4. Qatar market estimates and forecasts 2021 to 2033 (USD Million)

9.3.6. Rest of Middle East

9.3.6.1. Key country dynamics

9.3.6.2. Regulatory framework/ reimbursement structure

9.3.6.3. Competitive scenario

9.3.6.4. Rest of Middle East market estimates and forecasts 2021 to 2033 (USD Million)

CHAPTER 10. COMPETITIVE LANDSCAPE

10.1. Company/Competition Categorization

10.2. Strategy Mapping

10.3. Company Market Share Analysis, 2024

10.4. List of Key Certification Providers/Scheme Owners

10.5. Company Profiles/Listing

10.5.1. F. Hoffmann-La Roche AG

10.5.1.1. Company overview

10.5.1.2. Financial performance

10.5.1.3. Product benchmarking

10.5.1.4. Strategic initiatives

10.5.2. Abbott

10.5.2.1. Company overview

10.5.2.2. Financial performance

10.5.2.3. Product benchmarking

10.5.2.4. Strategic initiatives

10.5.3. Thermo Fisher Scientific Inc

- 10.5.3.1. Company overview
- 10.5.3.2. Financial performance
- 10.5.3.3. Product benchmarking
- 10.5.3.4. Strategic initiatives

10.5.4. Eurofins Scientific

- 10.5.4.1. Company overview
- 10.5.4.2. Financial performance
- 10.5.4.3. Product benchmarking
- 10.5.4.4. Strategic initiatives

10.5.5. QIAGEN

- 10.5.5.1. Company overview
- 10.5.5.2. Financial performance
- 10.5.5.3. Product benchmarking
- 10.5.5.4. Strategic initiatives

10.5.6. Bio-Rad Laboratories, Inc.

- 10.5.6.1. Company overview
- 10.5.6.2. Financial performance
- 10.5.6.3. Product benchmarking
- 10.5.6.4. Strategic initiatives

10.5.7. Siemens Healthineers AG

- 10.5.7.1. Company overview
- 10.5.7.2. Financial performance
- 10.5.7.3. Product benchmarking
- 10.5.7.4. Strategic initiatives

10.5.8. Merck KGaA

- 10.5.8.1. Company overview
- 10.5.8.2. Financial performance
- 10.5.8.3. Product benchmarking
- 10.5.8.4. Strategic initiatives

10.5.9. PerkinElmer Inc.

- 10.5.9.1. Company overview
- 10.5.9.2. Financial performance
- 10.5.9.3. Product benchmarking
- 10.5.9.4. Strategic initiatives

10.5.10. Agilent Technologies, Inc.

- 10.5.10.1. Company overview
- 10.5.10.2. Financial performance
- 10.5.10.3. Product benchmarking

10.5.10.4. Strategic initiatives

List Of Tables

LIST OF TABLES

Table 1 Middle East biomarker-based immunoassays market, by region, 2021 - 2033 (USD Million)

Table 2 Middle East biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)

Table 3 Middle East biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)

Table 4 Middle East biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)

Table 5 Middle East biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)

Table 6 Middle East biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)

Table 7 Saudi Arabia biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)

Table 8 Saudi Arabia biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)

Table 9 Saudi Arabia biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)

Table 10 Saudi Arabia biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)

Table 11 Saudi Arabia biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)

Table 12 UAE biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)

Table 13 UAE biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)

Table 14 UAE biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)

Table 15 UAE biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)

Table 16 Middle East biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)

Table 17 Kuwait biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)

Table 18 Kuwait biomarker-based immunoassays market, by product, 2021 - 2033

(USD Million)

Table 19 Kuwait biomarker-based immunoassays market, by biomarkers, 2021 - 2033

(USD Million)

Table 20 Kuwait biomarker-based immunoassays market, by diseases, 2021 - 2033

(USD Million)

Table 21 Kuwait biomarker-based immunoassays market, by end use, 2021 - 2033

(USD Million)

Table 22 Oman biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)

Table 23 Oman biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)

Table 24 Oman biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)

Table 25 Oman biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)

Table 26 Oman biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)

Table 27 Qatar biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)

Table 28 Qatar biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)

Table 29 Qatar biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)

Table 30 Qatar biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)

Table 31 Qatar biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)

List Of Figures

LIST OF FIGURES

- Fig. 1 Middle East biomarker-based immunoassays market segmentation
- Fig. 2 Data analysis biomarkers
- Fig. 3 Market formulation and validation
- Fig. 4 Data validating & publishing
- Fig. 5 Market research process
- Fig. 6 Information procurement
- Fig. 7 Primary research
- Fig. 8 Value-chain-based sizing & forecasting
- Fig. 9 QFD biomarker modelling for market share assessment
- Fig. 10 Market formulation & validation
- Fig. 11 Commodity flow analysis
- Fig. 12 Market outlook
- Fig. 13 Segment snapshot - 1
- Fig. 14 Segment snapshot - 2
- Fig. 15 Competitive landscape snapshot
- Fig. 16 Market trends & outlook
- Fig. 17 Porter's five force analysis
- Fig. 18 PESTEL analysis
- Fig. 19 Middle East biomarker-based immunoassays market: Sample outlook key takeaways
- Fig. 20 Middle East biomarker-based immunoassays market: Sample movement analysis
- Fig. 21 Blood market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 22 Tissue market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 23 Saliva market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 24 Urine market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 25 Middle East biomarker-based immunoassays market: Product outlook key takeaways
- Fig. 26 Middle East biomarker-based immunoassays market: Product movement analysis
- Fig. 27 Consumables market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 28 Instruments/Analyzers market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 29 Reagent & kits market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 30 Services market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 31 Middle East biomarker-based immunoassays market: Biomarker outlook key takeaways

Fig. 32 Middle East biomarker-based immunoassays market: Biomarker movement analysis

Fig. 33 Safety & toxicity biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 34 Efficacy & pharmacodynamic biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 35 Predictive & prognostic biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 36 Surrogate/Exploratory biomarkers estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 37 Middle East biomarker-based immunoassays market: Biomarker outlook key takeaways

Fig. 38 Middle East biomarker-based immunoassays market: Biomarker movement analysis

Fig. 39 Cancer market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 40 Cardiovascular diseases market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 41 Neurological diseases market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 42 Immunological diseases estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 43 Others market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 44 Middle East biomarker-based immunoassays market: End Use outlook key takeaways

Fig. 45 Middle East biomarker-based immunoassays market: End Use movement analysis

Fig. 46 Hospitals and clinics market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 47 Diagnostic laboratories market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 48 Research & academic institutes market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 49 Others estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 50 Biomarker-based immunoassays market: Regional outlook and key takeaways

Fig. 51 Regional outlook, 2024 & 2033

Fig. 52 Middle East

Fig. 53 Middle East market estimates and forecast, 2021 - 2033 (USD Million)

Fig. 54 Saudi Arabia key country dynamics

Fig. 55 Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)

Fig. 56 UAE key country dynamics

Fig. 57 UAE market estimates and forecast, 2021 - 2033 (USD Million)

Fig. 58 Kuwait key country dynamics

Fig. 59 Kuwait market estimates and forecast, 2021 - 2033 (USD Million)

Fig. 60 Oman key country dynamics

Fig. 61 Oman market estimates and forecast, 2021 - 2033 (USD Million)

Fig. 62 Qatar key country dynamics

Fig. 63 Qatar market estimates and forecast, 2021 - 2033 (USD Million)

Fig. 64 Market differentiators

Fig. 65 Key company market share analysis

I would like to order

Product name: Middle East Biomarker-Based Immunoassays Market Size, Share & Trends Analysis Report By Sample (Blood, Saliva) By Product (Reagents & Kits, Consumables), By Biomarker, By Diseases, By End Use, By Region, And Segment Forecasts, 2025 - 2033

Product link: <https://marketpublishers.com/r/MFD8305020ABEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MFD8305020ABEN.html>